Profile of COVID-19 Patients in Dr. Moewardi Hospital Surakarta Indonesia
DOI:
https://doi.org/10.3889/oamjms.2021.7522Keywords:
COVID-19, SARS-CoV-2, ComorbidAbstract
BACKGROUND: The 2019 coronavirus disease has been declared by WHO as a pandemic that has spread throughout the world since March 2020.
AIM: This study was conducted to determine the profile of COVID-19 patients at Dr. Moewardi hospital Surakarta.
METHODS: This study is a retrospective descriptive study, with the population and study samples taken from medical records of patients with a diagnosis of COVID-19 or SARS-CoV-2.
RESULTS: male sex with a total of 42 patients (47.72%) and female sex 46 patients (52.57%). The highest age group was in the age group 40-59 years with 46 patients (52.27%), with the most comorbid history being cardiovascular disease 31 patients (35.22%). The mean cytokine analysis of 88 patients includes examination of IL-1 that is equal to 73.95 and TNF-α with a mean of 67.19. The mean shows an increase above the normal value.
CONCLUSION: There is no difference between the sexes of men and women. The highest age range is in the 40-59-year age group. The most common comorbid history is cardiovascular disease. And the average patient showed increased levels of IL-1 and TNF-α.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Pramana C, Herawati S, Santi N, Rosreri, Maryani LP, Dachliana OR. The first case of COVID-19 in Semarang, Indonesia: A case report. Int J Pharm Res. 2020;12(2):1875-1878. DOI: https://doi.org/10.2139/ssrn.3759957
WHO. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19-11 March 2020; 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 [Last accessed on 2020 Mar 11].
Telles CR, Roy A, Ajmal MR, Mustafa SK, Ahmad MA, de la Serna JM, et al. The impact of COVID-19 management policies tailored to airborne SARS-CoV-2 transmission: Policy analysis. JMIR Public Health Surveill. 2021;7(4):e20699. https://doi.org/10.2196/20699 PMid:33729168 DOI: https://doi.org/10.2196/20699
Syed Khalid M, Aljohani MM, Alomrani NA, Oyoun AA, Alzahrani O, Ahmad MA, et al. COVID-19 and immune function-“a significant” Zinc. Orient J Chem. 2020;36(6):1026-36. DOI: https://doi.org/10.13005/ojc/360604
Mustafa SK, Ahmad MA, Baranova V, Deineko Z, Lyashenko V. Using wavelet analysis to assess the impact of COVID-19 on changes in the price of basic energy resources. Int J Emerg Trends Eng Res. 2020;8(7):2907-12. DOI: https://doi.org/10.30534/ijeter/2020/04872020
Zheng M, Wang X, Guo H, Fan Y, Song Z, Lu Z, et al. The cytokine profiles and immune response are increased in COVID-19 patients with Type 2 diabetes mellitus. J Diabetes Res. 2021;2021:9526701. https://doi.org/10.1155/2021/9526701 PMid:33490288 DOI: https://doi.org/10.1155/2021/9526701
Siemieniuk RAC, Bartoszko JJ, Díaz Martinez JP, Kum E, Qasim A, Zeraatkar D, et al. Antibody and cellular therapies for treatment of COVID-19: A living systematic review and network meta-analysis. BMJ. 2021;374:n2231. https://doi.org/10.1136/bmj.n2231 PMid:34556486 DOI: https://doi.org/10.1136/bmj.n2231
Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123-30. https://doi.org/10.1080/22221751.2020.1770129 PMid:32475230 DOI: https://doi.org/10.1080/22221751.2020.1770129
Shaikh FS, Aldhafferi N, Buker A, Alqahtani A, Dey S, Abdulhamid S, et al. Comorbidities and risk factors for severe outcomes in COVID-19 patients in Saudi Arabia: A retrospective cohort study. J Multidiscip Healthc. 2021;14:2169-83. https://doi.org/10.2147/JMDH.S31788 PMid:34408431 DOI: https://doi.org/10.2147/JMDH.S317884
Merza MY, Hwaiz RA, Hamad BK, Mohammad KA, Hama HA, Karim AY. Analysis of cytokines in SARS-CoV-2 or COVID-19 patients in Erbil city, Kurdistan region of Iraq. PLoS One. 2021;16(4):e0250330. https://doi.org/10.1371/journal.pone.0250330 PMid:33914789 DOI: https://doi.org/10.1371/journal.pone.0250330
Liu QQ, Cheng A, Wang Y, Li H, Hu L, Zhao X, et al. Cytokines and their relationship with the severity and prognosis of Coronavirus disease 2019 (COVID-19): A retrospective cohort study. BMJ Open. 2020;10(11):e041471. https://doi.org/10.1136/bmjopen-2020-041471 PMid:33257492 DOI: https://doi.org/10.1136/bmjopen-2020-041471
Guan WJ, Liang WH, He JX, Zhong NS. Cardiovascular comorbidity and its impact on patients with COVID-19. Eur Respir J. 2020;55(6):2001227. https://doi.org/10.1183/13993003.01227-2020 PMid:32341104 DOI: https://doi.org/10.1183/13993003.01227-2020
Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with Coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020;99:47-56. https://doi.org/10.1016/j.ijid.2020.07.029 PMid:32721533 DOI: https://doi.org/10.1016/j.ijid.2020.07.029
McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, et al. Characterization of the inflammatory response to severe COVID-19 Illness. Am J Respir Crit Care Med. 2020;202(6):812-21. https://doi.org/10.1164/rccm.202005-1583OC PMid:32584597 DOI: https://doi.org/10.1164/rccm.202005-1583OC
Fathi M, Vakili K, Sayehmiri F, Mohamadkhani A, Hajiesmaeili M, Rezaei-Tavirani M, et al. The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. PLoS One. 2021;16(2):e0246190. https://doi.org/10.1371/journal.pone.0246190 PMid:33592019 DOI: https://doi.org/10.1371/journal.pone.0246190
Rabaan AA, Al-Ahmed SH, Muhammad J, Khan A, Sule AA, Tirupathi R, et al. Role of inflammatory cytokines in COVID-19 patients: A review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines. 2021;9(5):436. https://doi.org/10.3390/vaccines9050436 PMid:33946736 DOI: https://doi.org/10.3390/vaccines9050436
Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-43. https://doi.org/10.1038/s41591-020-1051-9 PMid:32839624 DOI: https://doi.org/10.1038/s41591-020-1051-9
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Cahyono Hadi, Cipta Pramana (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
